On 26 April 2013, orphan designation (EU/3/13/1125) was granted by the European Commission to Voisin Consulting S.A.R.L, France, for (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one (duvelisib) for the treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma.
The sponsorship was transferred to Abbvie Ltd, United Kingdom, in November 2015, then to Voisin Consulting S.A.R.L., France, in September 2016 and finally to Verastem Europe GmbH, Germany, in November 2019.
This medicine is now known as duvelisib.
Please note that this product (marketed as Copiktra) was withdrawn from the Union Register of orphan medicinal products in March 2021 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.
EU/3/13/1125: Public summary of opinion on orphan designation: (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one for the treatment of chronic lymphocytic leukaemia/small lymphocytic lymphoma (PDF/208.1 KB)
First published: 14/05/2013
Last updated: 31/05/2021
Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma
|Date of designation||
|Orphan designation status||
|EU designation number||
Review of designation
Sponsor's contact details
Verastem Europe GmbH
Lange Strasse 70
Lower Saxony 29664
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.